M olecular chaperones are highly conserved proteins which either work passively, by preventing the aggregation of damaged proteins, or actively, via an ATPdriven conformational folding of target proteins (1) . The 90-kDa heat shock protein (Hsp90) 2 is an important ubiquitously expressed molecular chaperone that participates in the folding, assembly, maturation, and stabilization of various cellular proteins, particularly those involved in signal transduction, cell-cycle control, transcriptional regulation, and survival (2) . Hsp90 also influences the activity of the number of client proteins that function as key regulators of cellular growth, differentiation, and apoptosis (3). More than 100 known Hsp90 client proteins regulate multiple signal transduction pathways in human malignancies: transmembrane tyrosine kinases (HER-2/neu, epidermal growth factor receptor; c-Met and insulin-like growth factor-1 receptor); signaling proteins (Akt, Raf-1, and IB kinase); mutated signaling proteins (p53, Kit, Flt3, and v-src); chimeric signaling proteins (NPM-ALK, Bcr-Abl); steroid receptors (androgen, estrogen, and progesterone receptors); and cell-cycle regulators (cdk4, cdk6) (4 -16) . It also assists in maintaining the conformation of the MHC complex, T and B cell receptors, and many other key proteins involved in the normal function of immune cells (17) (18) (19) (20) . Hsp90, regulated by cochaperone proteins, participates in a series of dynamic multiprotein complexes linked to its ATPase activity (21, 22) . Of note, Hsp90 extracted from malignant cells was shown to have significantly higher ATPase activity and ATP-binding affinity compared with Hsp90 extracted from various normal cells (23) . As a number of Hsp90 client proteins promote cancer cell growth and survival, Hsp90 has emerged as an important target for cancer therapy.
The naturally occurring ansamycin antibiotic geldanamycin binds to the conserved N-terminal binding pocket in the ATPbinding domain of Hsp90 (24 -26) and inhibits ATP-dependent Hsp90 chaperone activity (27) (28) (29) , thereby leading to proteasomal degradation of the client proteins (30, 31) . Geldanamycin and its less toxic derivative 17-allylaminogeldanamycin (17-AAG) induce degradation of Hsp90 client proteins (32) (33) (34) and exert a potent antitumor activity (15) . This agent is currently being evaluated in clinical trial to treat patients with relapsed multiple myeloma as well as other cancers (35) (36) (37) .
Although the role of Hsp90 inhibition has been extensively studied in malignant cells, its effects on human immune cell function, especially the ability of dendritic cells (DC) to induce Ag-specific immunity, have not been well-known. In this study, we examined the impact of Hsp90 inhibition on the phenotype and function of immature (immDC) and mature DC (mDC) to evaluate how immune responses are modulated by inhibition of Hsp90. We show in this study that Hsp90 inhibition in DC significantly decreases expression of critical molecules, at the levels of RNA, surface protein as well as intracellular protein. This down-regulation by Hsp90 inhibition interferes with exogenous Ag uptake and interruption of the ability of mDC to stimulate allogeneic or Ag-specific autologous T cell responses.
Pharmingen. Geldanamycin was used as Hsp90 inhibitor, and it was obtained from the National Cancer Institute (Bethesda, MD).
Generation of monocyte-derived DCs and treatment with the Hsp90 inhibitor
PBMC were isolated from leukopaks obtained from normal donors by standard density gradient centrifugation over Ficoll-Paque Plus (Amersham Biosciences). To generate immDC, the monocytes obtained as the adherent cells from PBMC were cultured for 7 days in the presence of 1000 U/ml GM-CSF and 1000 U/ml IL-4 in RPMI 1640 medium (Invitrogen Life Technologies) supplemented with 10% FCS (BioWhittaker). Fresh medium plus GM-CSF and IL-4 was added to the cultures every other day. The mDC were obtained by adding 1000 U/ml IFN-␣ plus 10 ng/ml TNF-␣ along with fresh GM-CSF (1000 U/ml) and IL-4 (1000 U/ml) in 10% FCS-RPMI 1640 on day 7 and then incubating for an additional 3 days. Alternatively, DC were matured with 1 ng/ml LPS (Sigma-Aldrich) for determining IL-12 secretion from the culture. The immDC and mDC were treated with 1 M Hsp90 inhibitor for 24 or 48 h at 37°C and 5% CO 2 , evaluated for phenotypic and functional changes, and compared with untreated immDC and mDC.
Isolation of CD3
ϩ T cells T cells from normal donors were obtained from the nonadherent cell fraction using the Pan T Cell Isolation kit from Miltenyi Biotec. In brief, T cell enrichment was accomplished by depletion of B cells, NK cells, early erythroid cells, platelets, and basophils by labeling with a mixture of hapten-conjugated anti-CD11b, -CD16, -CD19, -CD36, and -CD56 Abs with MAC microbeads coupled to an anti-hapten mAb. The effluent (negative cell fraction) was collected from the column as enriched CD3 ϩ T cells. Purity (mean Ϯ SD) of the enriched CD3 ϩ T cells by flow cytometry was 95 Ϯ 2%. Purified CD3 ϩ T cells were used as responder cells to evaluate the functional activity of mDC.
Cell survival, apoptosis, and phenotypic analysis
Cell viability of untreated or Hsp90 inhibitor-treated DC was determined by trypan blue exclusion staining. Results are expressed as the percent of live cells ((viable treated DC/viable untreated control DC) ϫ 100). Effect of Hsp90 inhibitor on induction of apoptosis was examined using the Annexin V/PI-Apoptosis kit (Molecular Probes) as per the manufacturer's instruction. The surface protein expression on immDC and mDC was evaluated using mouse anti-human mAb conjugated with FITC or PE, which are specific to CD40, CD80, CD83, CD86, HLA-A, B, C, or HLA-DP, DQ, DR Ags. Following staining, the cells were analyzed using a FACSCalibur flow cytometer and CellQuest version 2.1 software (BD Biosciences). To estimate the recovery status of DC surface protein, Hsp90 inhibitor treated or untreated DC were extensively washed, recultured in fresh medium containing GM-CSF (1000 U/ml) plus IL-4 (1000 U/ml) for immDC or IFN-␣ (1000 U/ml) plus TNF-␣ (10 ng/ml) along with GM-CSF and IL-4 for mDC. Then, their cell surface expression levels were re-evaluated after 24, 48, and 72 h of incubation. Results (mean Ϯ SE, n ϭ 3) are expressed as the mean fluorescence intensity (MFI) or percent-positive cells.
Oligonucleotide microarray analysis of gene expression
Total RNA was extracted from immDC or mDC treated with Hsp90 inhibitor (1 M for 24 h) vs untreated control immDC or mDC using an RNeasy kit (Qiagen). RNA concentration was determined by absorbency at 260 nm and 15 g of high-quality total RNA was used in a cDNA synthesis reaction using the Megascript T7 kit (Ambion). The resulting cDNA was subsequently used to generate biotin-labeled antisense cRNA for hybridization with Human Genome HG-U133A Affymetrix gene chips. Scanning of image output files and analysis of gene expression data sets were followed by filtering of up-regulated or down-regulated transcripts, based on conventional criteria for statistical significance as well as by hierarchical and functional clustering algorithms (38 -40) .
Western blotting
Approximately 100 g of protein was suspended in Laemmli's sample buffer (0.1 M Tris-Cl buffer (pH 6.8), containing 1% SDS, 0.05% 2-ME, 10% glycerol, and 0.001% bromphenol blue), boiled for 2 min, and electrophoresed on 8 -16% SDS-polyacrylamide gels (Invitrogen Life Technologies) for 2 h at 80 V. A 10-kDa protein ladder was used as a size marker (Invitrogen Life Technologies). Gels were electroblotted onto nitrocellulose paper (Trans-Blot, 0.2-m transfer membrane; Bio-Rad) at 40 V for 2 h in Tris-glycine. Western blotting was performed following our earlier protocol with minor modifications (41) . Briefly, transfer was confirmed by Ponceau S staining, and nonspecific binding on the blots were blocked with 3% nonfat dry milk in PBS containing 0.2% Tween 20 (PBST). Incubation with mouse anti-human CD40 or CD83 Abs (Santa Cruz Biotechnology) was performed for 1 h in PBST containing 1% BSA with constant rocking. Blots were washed three times with PBST, and then incubated in anti-mouse HRP conjugates for 1 h in PBST containing 3% nonfat dry milk. After washing, specific proteins were detected using ECL, according to the instructions provided by manufacturer (Amersham Life Sciences).
Induction of IL-12 secretion by mDC
IL-12 secretion by either Hsp90 inhibitor-treated or untreated mDC was measured using a human IL-12 ELISA kit (BD Biosciences). Briefly, supernatants from culture of DC matured with LPS (1 ng/ml), along with IL-12 as standards, were transferred into wells of a 96-well plate precoated with a monoclonal anti-human IL-12 capture Ab and incubated for 2 h at room temperature. After washing the plate with PBS/0.05% Tween 20, the buffer containing detection Ab and streptavidin-HRP conjugate was added to each well and incubated for 1 h at room temperature. The wells were washed and then developed by incubation with substrate solution for 30 min. Stop solution was added to each well and the absorbance was determined at 450 nm with a PerkinElmer Wallac Victor2 counter. The amount of IL-12 present in the mDC culture supernatant was calculated based on the IL-12 standard curve. 
Ag uptake by immDC
Ability of immDC to uptake Ag was evaluated using a variety of sizes and forms of Ags including 40-kDa Dextran-FITC (1 mg/ml; Molecular Probes), 45-kDa protein A-Alexa Fluor 488 (200 g/ml; Molecular Probes), or 20-kDa protein G-Alexa Fluor 488 (200 g/ml; Molecular Probes). In brief, Hsp90 inhibitor-treated or untreated immDC (3 ϫ 10 5 ) were pulsed with respective Ag, incubated at 37°C for 45 min, washed three times with cold RPMI 1640, resuspended in 1% paraformaldehyde, and analyzed by flow cytometry. To examine the modification of Ag uptake receptors on immDC, the expression level of mannose receptor, DEC-205 or Fc␥RIII, was analyzed by flow cytometry using specific Abs.
Ag processing and presentation by immDC
Hsp90 inhibitor-treated or untreated immDC were pulsed with tetanus toxoid (0.5 g/ml; Calbiochem) overnight. Following washing, DC were matured with TNF-␣ (10 ng/ml) and IFN-␣ (1000 U/ml), and gamma-irradiated (10 Gy) using a cesium 137 ( 137 Cs) gamma irradiator source. The mDC were then cocultured with autologous T cells labeled with CFSE (Molecular Probes) to measure the proliferation status of the T cells. For CFSE labeling, T cells were washed, resuspended in 5% FCS-PBS at 2 ϫ 10 6 /ml, and stained with CFSE in DMSO at a final concentration of 5 M for 10 min at 37°C. T cells were then washed three times and resuspended in AIM-V medium supplemented with 10% human AB serum (BioWhittaker) and 50 U/ml IL-2. After 6 days of coculture of CFSE-labeled T cells (1 ϫ 10 6 /well) with DC (1 ϫ 10 5 /well), proliferation status of the T cells was examined by flow cytometric analysis.
Ag presentation by mDC and induction of T cell proliferation
Allogeneic T cell stimulatory capacity of Hsp90-inhibited DC was assessed. DC were incubated with the Hsp90 inhibitor for 24 h during or after FIGURE 2. Irreversible down-regulation of key surface molecules on immDC and mDC by Hsp90 inhibition. a, immDC, untreated (Ⅺ) or treated (f) with Hsp90 inhibitor for 24 h, were analyzed for expression of key cell surface molecules using specific Abs by flow cytometry; results are presented as MFI (mean Ϯ SE, n ϭ 3) of cell surface expression of each Ag (CD40, CD80, CD83, CD86, HLA-A, B, C, and HLA-DP, DQ, DR). Surface Ag expression was significantly decreased on the immDC after 24 h of Hsp90 inhibition. b, immDC were treated with the Hsp90 inhibitor for 24 h, extensively washed, and cultured for 3 days. Cells were analyzed by flow cytometry on days 1-3 for expression of costimulatory molecule (CD86) and MHC class I molecules (HLA-A, B, C) by MFI or the percentage of positive cells. No recovery of Ag expression was observed on the immDC on days 1, 2, or 3 following removal of the Hsp90 inhibitor. c, mDC, untreated (Ⅺ) or treated (f) with Hsp90 inhibitor for 24 h, were analyzed for expression of key cell surface molecules (CD40, CD80, CD83, CD86, HLA-A, B, C, and HLA-DP, DQ, DR). Significant decrease was observed in MFI (mean Ϯ SE, n ϭ 3) of all Ags tested on mDC by Hsp90 inhibition. d, Expression of costimulatory molecule (CD86) was analyzed on mDC, treated with Hsp90 inhibitor for 24 h, extensively washed, and cultured for 3 days. As for immDC, mDC showed down-regulation of surface molecule expression, which did not recover up to 3 days after extensive washings of the Hsp90 inhibitor from the culture. 
Release of IFN-␥ by allogeneic T cells stimulated with mDC

IFN-␥ release by the allogeneic CD3
ϩ T lymphocytes following coculture with either Hsp90 inhibitor-treated or untreated mDC for 24 h was measured using a human IFN-␥ ELISA kit (BD Biosciences). Briefly, purified IFN-␥ as standard and T cell culture supernatants were transferred onto a 96-well plate precoated with a monoclonal anti-human IFN-␥ capture Ab, incubated for 2 h at room temperature, and analyzed with ELISA as described above. Cytokine present in the CTL culture supernatant was quantitated based on an IFN-␥ standard curve.
Results
Hsp90 inhibition decreases cell surface expression of key molecules on immDC and interferes with DC maturation
We first evaluated the effect of Hsp90 inhibition on survival of both immDC and mDC by examining viable cell number and induction of apoptosis, as measured by trypan blue staining and annexin V staining, respectively, following 24 h treatment with 1 M Hsp90 inhibitor. Hsp90 inhibition did not affect cell survival (Fig.  1a) or induce apoptosis (Fig. 1b) in immDC and mDC.
The effect of Hsp90 inhibition on the expression of critical cell surface markers was next examined on immDC and mDC using flow cytometry. As seen in Fig. 2a , Hsp90 inhibition significantly ( p Ͻ 0.05) down-regulated surface expression of costimulatory (CD40, CD80, CD86), maturation (CD83), and MHC (HLA-A, B, C and HLA-DP, DQ, DR) Ags on immDC at 24 h. To assess whether the immDC recover expression of the surface molecules following 24 h treatment with Hsp90 inhibitor, immDC were washed extensively to remove Hsp90 inhibitor and recultured in fresh medium containing GM-CSF and IL-4. The surface expression of the costimulatory, maturation, and MHC Ags was then analyzed for 3 days. As seen in Fig. 2b , the surface expression of Ags on immDC did not recover, as assessed by either MFI or percent-positive cells for 3 days, following removal of Hsp90 inhibitor, demonstrating that inhibition of Hsp90 irreversibly interrupts the expression of critical surface molecules on immDC.
Next, the effect of Hsp90 inhibition on DC maturation was evaluated by adding the inhibitor at the last 24 h of culture during DC maturation with IFN-␣ and TNF-␣. As seen in Fig. 2c , Hsp90 inhibition decreased cell surface expression of costimulatory (CD40, CD80, CD86), maturation (CD83) and MHC (HLA-A, B, C and HLA-DP, DQ, DR) molecules on mDC. In addition, removal of the inhibitor by extensive washing followed by reculturing in fresh medium containing GM-CSF, IL-4, IFN-␣, and TNF-␣ for next 3 days did not lead to recovery of surface expression of these molecules including CD86 (Fig. 2d) , suggesting that inhibition of protein folding during DC maturation irreversibly interferes with the maturation process.
Hsp90 inhibition down-regulates gene as well as intracellular protein expression
To investigate the effect of Hsp90 inhibition on RNA expression of key molecules in both immDC and mDC, we evaluated the changes in the gene expression profiles of these molecules in immDC and mDC using HG-U133A gene arrays, with or without Hsp90 inhibitor treatment (1 M for 24 h). As seen in Fig. 3 , the expression of molecules critical for DC function, including CD40, CD80, CD83, CD86, HLA-A, B, C, and HLA-DP, DQ, DR, was down-regulated in immDC and mDC following Hsp90 inhibition.
To evaluate for corresponding changes in intracellular protein levels following Hsp90 inhibitor treatment, lysates of untreated and treated DC were analyzed by Western blots for the expression of CD40 and CD83. As can be seen in Fig. 4 , Hsp90 inhibition decreased intracellular protein levels of CD40 and CD83 in both immDC (CD40: 2.50-fold, CD83: 3.33-fold) and mDC (CD40: 2.50-fold, CD83: 1.40-fold) compared with control untreated DC. These results are consistent with the observed down-regulation of gene expression as well as cell surface protein expression following Hsp90 inhibition.
Hsp90 inhibition decreases Ag uptake, processing, and presentation by immDC
A key function of immDC is Ag uptake, before their processing and presentation to T cells. We therefore investigated the effect of Hsp90 inhibition on Ag uptake by immDC. Hsp90 inhibited (1 M for 24 or 48 h) or control untreated immDC were pulsed with FITC-labeled Dextran, Alexa Fluor-labeled protein A or protein G at 37°C for 1 h. Uptake of these Ags by immDC was then measured by flow cytometry. As can be seen in Fig. 5a , Hsp90 inhibition led to a significantly reduced ( p Ͻ 0.05) uptake of all three Ags with different molecular masses and Ag properties both at 24 and 48 h. Next, we investigated effect of Hsp90 inhibitor on cell surface expression of mannose receptor, DEC 205, and Fc␥RIII, the receptors involved in Ag uptake by DC. Hsp90 inhibition decreased expression of mannose receptor as demonstrated by MFI as well as percent-positive cells (Fig. 5b) , which was associated with the observed reduction in Ag uptake. In contrast, neither DEC-205 nor Fc␥RIII expression was significantly changed by Hsp90 inhibition (Fig. 5b) .
To assess the ability of Hsp90 inhibitor-treated DC to process and present Ag, we measured their ability to process and present tetanus toxoid as a recall Ag and to stimulate proliferation of autologous T lymphocytes. immDC, with and without Hsp90 inhibitor treatment (1 M for 24 h), were pulsed with tetanus toxoid and used to stimulate CFSE-labeled T cells after the DC maturation. After 6 days incubation, T cell proliferation was measured as a shift in the proportion of cells labeled with CFSE by flow cytometry. In comparison with T cells alone (1%) (Fig. 6a) or T cells cultured with unpulsed DC (11%) (Fig. 6b) , T cells stimulated with tetanus toxoid-pulsed DC (Fig. 6c) showed higher proliferation (73%), gated in M1. However, when Hsp90 inhibitor-treated DC pulsed with tetanus toxoid were used, T cell proliferation was significantly decreased (47%) (Fig. 6d) . These results suggest that DC lose their Ag processing and presentation capability following Hsp90 inhibition.
Hsp90 inhibition reduces ability of mDC to induce allogeneic T cell response and to secrete IL-12
To further investigate the functional effects of Hsp90 inhibition on DC, we evaluated the ability of either untreated or Hsp90 inhibitor-treated mDC to induce allogeneic T cell responses. Hsp90 inhibitor was added, either during or after DC maturation, for 24 h. DC were harvested, washed, irradiated (10 Gy), and cocultured with allogeneic CD3 ϩ T cells for 5 days and T cell proliferation was evaluated by measuring [ 3 H]thymidine incorporation. As seen in Fig. 7 , untreated mDC induce allogeneic T cell proliferation through the presentation of mismatched MHC. However, Hsp90 inhibition, either during (Fig.  7aI) or after (Fig. 7aII) DC maturation, led to significant ( p Ͻ 0.05) reduction in their ability to induce allogeneic T cell proliferation compared with untreated control DC. These results therefore demonstrate that DC lose their capacity to present Ag to allogeneic T cells following Hsp90 inhibition.
IL-12 plays a crucial role in polarizing Th1/Th2 responses, as well as cross-priming of CTL (42) (43) (44) (45) . We therefore next evaluated the effect of Hsp90 inhibition on the ability of mDC to secrete IL-12. The DC were matured with LPS (1 ng/ml) for 3 days and Hsp90 inhibitor was added to the DC culture for last 24 h of maturation. The secretion of IL-12 was examined from the culture of mDC obtained from three normal donors. As seen in Fig. 7b , Hsp90 inhibitor-treated mDC secreted significantly less IL-12 compared with untreated control mDC ( p Ͻ 0.05).
Hsp90 inhibition leads to defective T cell response
The effects of Hsp90 inhibitor on mDC function were then further analyzed by measuring their ability to induce IFN-␥ secretion by culturing with allogeneic T lymphocytes. The mDC generated from three normal donors were treated with Hsp90 inhibitor, washed, and cocultured for 24 h with allogeneic T lymphocytes obtained from two different normal donors. The high level of IFN-␥ secretion due to allogeneic T cell immune responses was detected in T cell cultures (donor 4 or 5) mixed with untreated mDC (donor 1, 2 or 3). However, allogeneic T lymphocytes cultured with Hsp90 inhibitor-treated mDC from all donors secreted significantly lesser amounts of IFN-␥ ( p Ͻ 0.05) compared with untreated control mDC (Table I) .
Discussion
The Hsp90 chaperone plays an important role in mediating immune functions. Hsp90 is involved in ATP-dependent assembly and function of the proteasomes, which produces the MHC class I ligands. The proteasome cap structure itself has chaperone activity, unfolding irreversibly damaged proteins and directing them to the active sites of the proteasomal core, where antigenic peptides are generated (46 -50) . In addition, like other cytoplasmic chaperones, Hsp90 participates in transporting, trimming, and presenting antigenic peptides to the MHC class I molecules to evoke T cell immune responses (51) (52) (53) . shown that processing of Ags is regulated mainly through Hsp90 by demonstrating enhanced processing of OVA by Hsp90.
The objective of the current study was to examine how Hsp90 affects survival, phenotype, proliferation, and function of immature and mature human DC. In contrast to its effects on malignant cells such as multiple myeloma cells (54 -56) , Hsp90 inhibition did not affect survival of immDC or mDC. However, it significantly affected cell surface expression of key costimulatory, as well as maturation and MHC, molecules critical for DC function. This decreased cell surface expression of proteins induced by Hsp90 inhibitor can be mediated via various mechanisms: decreased mRNA expression, as observed with gene expression profile data; blocking degradation of proteins that require Hsp90 as chaperone for their conformational maturation (57, 58) ; and/or altering proper protein assembly as well as folding, thereby affecting the tertiary structure of these proteins, and cell surface anchoring. The mechanism of functional effect of Hsp90 inhibition on DC is a complex interplay of various molecular changes that may involve changes at expression and protein folding level as well as eventual proteasomal degradation.
In our study, significant reduction in proliferation of T cells was observed by their coculture with Hsp90-inhibited DC compared with untreated DC pulsed with tetanus toxoid. This could be due to decreased uptake and/or processing of tetanus toxoid by immDC following Hsp90 inhibition, thereby resulting in poor Ag presentation to T cells. Besides tetanus toxoid, we also observed significant decrease in DC uptake of various other types and sizes of Ags, including dextran, protein A, and protein G following Hsp90 inhibition. In addition, lower expression of costimulatory and MHC molecules on DC following Hsp90 inhibition could also contribute to reduced T cell proliferation to tetanus toxoid stimulation. Under normal condition, mDC, efficiently presents Ag and induces T cell stimulation compared with immDC by expressing higher levels of CD80, 86, MHC class I and II molecules (59, 60) . Our study showed that cell proliferation was dramatically decreased when the allogeneic T lymphocytes were cultured with irradiated mDC treated with Hsp90 inhibitor, either during or after DC maturation. In addition, allogeneic T lymphocytes secreted significantly less IFN-␥ when stimulated with Hsp90 inhibitortreated mDC compared with untreated mDC. These results confirm that Hsp90 inhibition significantly affects normal immature and mDC function.
Molecular chaperones are required for stability and function of normal cellular proteins as well as mutated, chimeric, and overexpressed signaling proteins that promote cancer cell growth and/or survival (61) (62) (63) (64) (65) . Hsp90 in tumor cells is largely contained in multiprotein complexes and its ATPase activity is markedly higher in transformed cells compared with untransformed cells, in which Hsp90 is mostly uncomplexed. The aberrant overexpression of Hsp90-dependent oncoproteins, such as kinases or transcription factors, has been proposed as the cause for this difference, which may at least in part, account for the sensitivity of tumor cells to Hsp90-targeting agents (66) . The Hsp90 inhibitor, by interacting specifically with these molecular targets, causes destabilization and eventual degradation of Hsp90 client proteins, leading to apoptotic cell death. Hsp90 inhibitors have already shown promise as an antitumor agent in preclinical studies (67) . For example, Hsp90 inhibitor induces apoptotic cell death in both primary myeloma cells and myeloma cell lines in vitro and in vivo in murine models of human myeloma (54) . These preclinical data have led to an ongoing phase I clinical evaluation of the geldanamycin analog, 17 AAG, in multiple myeloma (56) . Other highly potent Hsp90 inhibitors, such as radicicol (68) and purine scaffold inhibitors (69) , are undergoing preclinical evaluation.
Because Hsp90-mediated protein processing and folding is critical for normal DC function, its inhibition could lead to significant modulation of DC-mediated immune responses with potential clinical effects. Our results suggest the need to closely monitor immune function in patients being treated with the Hsp90 inhibitor, in particular to monitor for immunosuppression and opportunistic infections. Also, its inhibitory effects on allogeneic MLR suggest that the Hsp90 inhibitor may be useful to treat or prevent graftvs-host disease, as well as certain autoimmune diseases.
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